Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 3Nelson Syndrome 2Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Carcinoma, Intraductal, Noninfiltrating 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

Temozolomide 2Filgrastim 2Everolimus 2trifluridine tipiracil drug combination 1sargramostim 1poly ICLC 1pegfilgrastim 1pasireotide 1gadobutrol 1gadobenic acid 1dactolisib 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Vaccines 1Topotecan 1Surgical Procedures, Operative 1Radiotherapy 1O(6)-benzylguanine 1Methylphenidate 1Magnetic Resonance Spectroscopy 1Genistein 1Gadolinium DTPA 1Decitabine 1Cyclophosphamide 1Congresses as Topic 1Carmustine 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive × pasireotide × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡